However, impact of adjuvant anti-HER2 targeted treatment on outcomes in metastatic setting of HER2+ relapsed patients with breast cancer are still undetermined, even if there is a trend toward a lower benefit in patients recurring after trastuzumab in early setting.17-21. This evidence concerns the gene ERBB2 and breast carcinoma.